$UNCY 4 SEC Filings

Filed On	Filing
21 May 2026	Form 4: Gupta Shalabh K., Director Granted 762,200 Restricted Stock Units
21 May 2026	Form 4: Kenkare-Mitra Sara, Director Granted 126,300 Restricted Stock Units
20 May 2026	Form 4: Jermasek Douglas, EVP, Corporate Strategy Granted 169,500 Restricted Stock Units
20 May 2026	Form 4: Gupta Pramod, EVP, Pharmaceuticals and BD Granted 169,500 Restricted Stock Unit
20 May 2026	Form 4: Townsend John, CFO Granted 169,500 Restricted Stock Unit
18 May 2026	Form 4: Laumas Sandeep, Director Granted 126,300 Restricted Stock Units
26 Aug 2025	Form 4: Aggarwal Gaurav, Director Received 652,900 shares by conversion · Disposed of 3,199.21 Series A-2 Prime Preferred Stock (Disposition to Issuer) ($3.2M)
30 Jul 2025	Form 4: Aggarwal Gaurav, Director Granted 21,200 Stock Options
30 Jul 2025	Form 4: Laumas Sandeep, Director Granted 21,200 Stock Options
30 Jul 2025	Form 4: Kenkare-Mitra Sara, Director Granted 21,200 Stock Options
30 Jul 2025	Form 4: Gupta Shalabh K., Director Granted 325,000 Stock Options
30 Jul 2025	Form 4: Townsend John, Chief Financial Officer Granted 10,000 Stock Options
30 Jul 2025	Form 4: Gupta Pramod, EVP, Pharmaceuticals and BD Granted 90,000 Stock Options
30 Jul 2025	Form 4: Jermasek Douglas, EVP of Corporate Strategy Granted 10,000 Stock Options
19 Feb 2025	Form 4: Aggarwal Gaurav, Director Received 1,400,000 shares by conversion · Disposed of 686 Series A-2 Prime Preferred Stock (Disposition to Issuer) ($686K)
10 Oct 2024	Form 4: Aggarwal Gaurav, Director Received 5,500,000 shares by conversion · Disposed of 2,695 Series A-2 Prime Preferred Stock (Disposition to Issuer) ($2.7M)
14 Aug 2024	Form 4: Townsend John, Chief Financial Officer Granted 40,256 Stock Options
14 Aug 2024	Form 4: Gupta Pramod, EVP, Pharmaceuticals and BD Granted 81,750 Stock Options
14 Aug 2024	Form 4: Jermasek Douglas, EVP of Corporate Strategy Granted 81,750 Stock Options
14 Aug 2024	Form 4: Gupta Shalabh K., Director Granted 232,868 Stock Options

Comments